AI assistant
ARS Pharmaceuticals, Inc. — Director's Dealing 2024
Dec 7, 2024
32159_dirs_2024-12-06_c0e4e748-90d6-4d88-a511-66ace20b7b90.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARS Pharmaceuticals, Inc. (SPRY)
CIK: 0001671858
Period of Report: 2024-12-04
Reporting Person: Chakma Justin (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-12-04 | Common Stock | M | 45000 | $0.84 | Acquired | 181380 | Direct |
| 2024-12-04 | Common Stock | S | 45000 | $13.9543 | Disposed | 136380 | Direct |
| 2024-12-05 | Common Stock | M | 49640 | $0.84 | Acquired | 186020 | Direct |
| 2024-12-05 | Common Stock | S | 49640 | $14.1346 | Disposed | 136380 | Direct |
| 2024-12-06 | Common Stock | M | 50000 | $0.84 | Acquired | 186380 | Direct |
| 2024-12-06 | Common Stock | S | 50000 | $14.2323 | Disposed | 136380 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-04 | Stock Option (Right to Buy) | $0.84 | M | 45000 | Disposed | 2029-07-04 | Common Stock (45000) | Direct |
| 2024-12-05 | Stock Option (Right to Buy) | $0.84 | M | 49640 | Disposed | 2029-07-04 | Common Stock (49640) | Direct |
| 2024-12-06 | Stock Option (Right to Buy) | $0.84 | M | 50000 | Disposed | 2029-07-04 | Common Stock (50000) | Direct |
Footnotes
F1: The weighted average sale price for the transaction reported was $13.9543, and the range of prices were between $13.77 and $14.28. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F2: The weighted average sale price for the transaction reported was $14.1346, and the range of prices were between $13.95 and $14.35. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F3: The weighted average sale price for the transaction reported was $14.2323, and the range of prices were between $14.00 and $14.48. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided.
F4: Immediately exercisable.